BUSINESS AND PROPERTY COURTS IN MANCHESTER
CIRCUIT COMMERCIAL COURT (QBD)
B e f o r e :
(sitting as a Judge of the High Court)
BETWEEN:
____________________
BIP CHEMICAL HOLDINGS LIMITED | Claimant | |
and | ||
MRS JEAN BLUNDELL | Defendant |
____________________
Lesley Anderson QC(instructed by Glaisyers Solicitors) for the Defendant
Hearing dates 7-9, 12-13 July 2021
____________________
Crown Copyright ©
HHJ Cadwallader
Introduction
The pleaded issues
Background
The SPA
(1) that since the Accounts Date [Centec's] business had been carried on in the normal and ordinary course without any interruption or change in its manner, nature or scope, and so as to maintain it as a going concern: paragraph 7.1
(2) that since the Accounts Date, so far as the Seller was aware, there had been no material adverse change in the financial or trading position, or turnover of [Centec] and so far as the Seller was aware there was no fact or circumstance which might give rise to such a change: paragraph 7.2
(3) that since the Accounts Date, [Centec] had not been adversely affected by the termination, or a change in the terms, of an important agreement: paragraph 7.4.1
(4) that since the Accounts Date, [Centec] had not been adversely affected by the loss of or material reduction in orders from a customer: paragraph 7.4.2
(5) that since the Accounts Date, [Centec] had not been adversely affected by the loss of or material reduction in any source of supply: paragraph 7.4.3
(6) that since the Accounts Date, [Centec] had not been adversely affected by any abnormal factor not affecting similar businesses to a similar extent: paragraph 7.4.4
(7) that since the Accounts Date, [Centec] had not been adversely affected by and so far as the Seller was aware there was no fact or circumstance which might give rise to any such adverse effect [as mentioned in paragraphs 7.4.1 to 7.4.4]: paragraph 7.4.5
(8) that [Centec] was not, or was not in negotiations to become, bound by or entitled to the benefit or any agreement or arrangement, or subject to any liability, which was of an unusual, onerous or abnormal nature or was not of an entirely arm's length nature: paragraph 14.1.1
(1) The total liability of the Seller for all claims was not to exceed 75% of the total consideration actually received by the Seller: paragraph 1.2
(2) importantly, "nothing in this Schedule 4 excludes or limits the liability of the Seller to the extent that a claim arises by reason of any fraud or fraudulent misrepresentation by or on behalf of the Seller": paragraph 3
(3) the Seller was not liable for a claim to the extent that the relevant liability would not have arisen but for an act or omission by the buyer or any of its directors, employees or agents at any time: paragraph 4.2.2.
The witnesses
The course of events
The meeting on 26 February 2019
27th of February 2019
"As the Blundell family has stepped back from the business during the current sale process, we do not have more recent financial information but our understanding is the management are forecasting EBITDA of £250K for the 12 months to December 2019".
3 March 2019
Completion
The warranty claims
Paragraph 14.1.1
Paragraph 7.1
Paragraph 7.2
"fairly disclosed in the Disclosure Letter or contained within the Disclosure Documents with sufficient clarity to enable the buyer to assess with reasonable accuracy the nature of the matter disclosed".
The Disclosure Letter lists the warranty provisions by number, and makes disclosures opposite them. The warranty at paragraph 7.2 is not listed, and accordingly no disclosure was made specifically in relation to it. However, the Letter (which was part of the SPA) explicitly states that the headings and numbering are for convenience only, and do not alter the construction of the letter nor in any way limit the effect of any of the disclosures,
"all of which are made against the relevant warranties as a whole. A disclosure or qualification made by reference to any particular paragraph of the relevant warranties schedule shall be deemed to be made. In respect of any other paragraph of the relevant warranties schedule to which the disclosure or qualification may be applicable".
Furthermore,
"where brief particulars only of a matter are set out or referred to in this letter, or a document is referred to but not attached, or a reference is made to a particular part only of such a document, full particulars of the matter and the full contents of the document are deemed to be disclosed, and it is assumed that the Buyer does not require any further particulars."
The Disclosure Letter forms part of the transaction agreements, and was signed on behalf of BIP as well as Mrs Blundell. The fact that no disclosure was made specifically against the warranty at paragraph 7.2 is not of any particular significance, therefore. The question is whether the Disclosure Letter contains disclosures which fairly disclose matters which would otherwise amount to a breach of this warranty with sufficient clarity to enable BIP to assess with reasonable accuracy the nature of the matter disclosed, brief particulars being sufficient.
Damages for breach of warranty
As warranted
As was
The misrepresentation claims
26 February 2019
27th February 2019
"as the Blundell family has stepped back from the business during the current sale process, we do not have more recent financial information but our understanding is the management are forecasting EBITDA of £250K for the 12 months to December 2019".
I have already indicated, that I do not regard the difference between target and projection as being material, and I accept Mr Donnan's evidence in that regard. The figure seems, again, to have come from Mr McGreal, as Mr Donnan described in his evidence. There is no indication that Mr Donnan was aware of the projected loss which I have already referred, and I accept his evidence that at the time he had not been aware of the negative EBITDA which was later applied to February 2019. Accordingly, I find that there was no misrepresentation through Mr Donnan.
3 March 2019
Conclusion on claim
Counterclaim and set-off
Conclusion